BIOMAT Database Logo BIOMAT Database Logo

Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in "non-critically-ill" patients on hemodialysis. 2021

Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Department of Medical and Surgical Sciences, Nephrology, Dialysis and Transplantation Unit, University of Foggia, Viale Luigi Pinto, 1, 71100, Foggia, Italy. giuseppe.castellano@unifg.it.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000093485 COVID-19 Drug Treatment The use of DRUGS to treat COVID19 or its symptoms. COVID-19 Drug Therapy,COVID19 Drug Therapy,COVID19 Drug Treatment,Coronavirus Disease 2019 Drug Treatment,Coronavirus Disease-19 Drug Treatment,COVID 19 Drug Therapy,COVID 19 Drug Treatment,COVID-19 Drug Therapies,COVID19 Drug Therapies,COVID19 Drug Treatments,Coronavirus Disease 19 Drug Treatment,Drug Therapy, COVID-19,Drug Therapy, COVID19,Therapy, COVID-19 Drug,Therapy, COVID19 Drug,Treatment, COVID-19 Drug
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
January 2021, JAMA internal medicine,
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Tocilizumab in critically ill COVID-19 patients: An observational study.
January 2022, International immunopharmacology,
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study.
April 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study.
February 2022, Antibiotics (Basel, Switzerland),
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Long term outcomes of critically ill COVID-19 pneumonia patients: early learning.
February 2021, Intensive care medicine,
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics.
March 2023, Journal of clinical medicine,
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Critically Ill vs. Non-Critically Ill Patients With COVID-19 Pneumonia: Clinical Features, Laboratory Findings, and Prediction.
January 2021, Frontiers in cellular and infection microbiology,
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Outcomes of Covid-19 organizing pneumonia in critically ill patients.
October 2021, The Journal of infection,
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Ventilator-associated pneumonia in critically ill patients with COVID-19.
January 2021, Critical care (London, England),
Giuseppe Castellano, and Barbara Infante, and Silvia Mercuri, and Mauro Forcella, and Sharon Natasha Cox, and Gaetano Serviddio, and Loreto Gesualdo, and Giovanni Stallone
Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.
March 2021, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine,
Copied contents to your clipboard!